Examining early‐onset Alzheimer’s disease (EOAD) and late‐onset Alzheimer’s disease to understand the neuropathological substract of typical and atypical AD

Lea Tenenholz Grinberg; Cathrine Petersen; Amber L. Nolan; Elisa de Paula França Resende; Zachary A. Miller; Salvatore Spina; Bruce L. Miller; Gil D. Rabinovici; William W. Seeley

Journal ArticleOPEN ACCESS

Examining early‐onset Alzheimer’s disease (EOAD) and late‐onset Alzheimer’s disease to understand the neuropathological substract of typical and atypical AD

Grinberg L
Petersen C
Nolan A
et al.

Alzheimer's & Dementia (2020) 16(S5)

DOI: 10.1002/alz.041616

N/ACitations

7Readers

Abstract

Background: Pathologically proven Alzheimer's disease (AD) manifest clinically with a

Cite

CITATION STYLE

APA

Grinberg, L. T., Petersen, C., Nolan, A. L., Resende, E. de P. F., Miller, Z. A., Spina, S., … Seeley, W. W. (2020). Examining early‐onset Alzheimer’s disease (EOAD) and late‐onset Alzheimer’s disease to understand the neuropathological substract of typical and atypical AD. Alzheimer’s & Dementia, 16(S5). https://doi.org/10.1002/alz.041616

Examining early‐onset Alzheimer’s disease (EOAD) and late‐onset Alzheimer’s disease to understand the neuropathological substract of typical and atypical AD

Abstract

Cite

Register to see more suggestions